FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashing	ton. D).C. 2	20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Powl Brian T.				2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]								ationship of k all applica Director Officer (,	10)% Owi	ner		
	E THERAI	PEUTICS, INC.	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/06/2023						Λ	below)			,			
12278 SC	CRIPPS SU	MMIT DRIVE		4.	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DII	EGO C	A	92131										Line) X		ed by One F ed by More			ng
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			Transaction te onth/Day/	Execution Date,		Transaction Disposed Of Code (Instr.		ties Acquired (A) o d Of (D) (Instr. 3, 4 a				ly (6. Ownersh Form: Direc (D) or Indirec (I) (Instr. 4)	et Ir	7. Nature of ndirect Beneficial Ownership Instr. 4)			
							Code	v	Amount (A) or (D)		Pric	e	Transaction(s) (Instr. 3 and 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	Own Forn Direc or In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amour or Numbe of Shar	er		(Instr. 4)	(3)		
Stock Option (Right to Buy)	\$6.77	02/06/2023		Α		425,000		(1)	02	2/05/2033	Common Stock	425,0	000	\$0.00	425,000		D	

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.

Remarks:

/s/ Cindy Tahl, as Attorney-in-**Fact**

02/07/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.